Wellington Management Group LLP Increases Stock Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Wellington Management Group LLP boosted its position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 22.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 389,706 shares of the company's stock after acquiring an additional 72,432 shares during the period. Wellington Management Group LLP owned 0.27% of MiMedx Group worth $3,749,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. Norges Bank bought a new stake in shares of MiMedx Group in the fourth quarter worth about $4,020,000. JPMorgan Chase & Co. lifted its holdings in MiMedx Group by 133.1% in the 4th quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company's stock worth $6,668,000 after buying an additional 395,739 shares during the period. Arrowstreet Capital Limited Partnership grew its position in shares of MiMedx Group by 484.2% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 362,481 shares of the company's stock worth $3,487,000 after buying an additional 300,433 shares during the last quarter. Jane Street Group LLC increased its stake in shares of MiMedx Group by 133.6% during the third quarter. Jane Street Group LLC now owns 305,652 shares of the company's stock valued at $1,806,000 after buying an additional 174,797 shares during the period. Finally, Barclays PLC increased its stake in shares of MiMedx Group by 163.9% during the third quarter. Barclays PLC now owns 262,449 shares of the company's stock valued at $1,550,000 after buying an additional 163,005 shares during the period. Hedge funds and other institutional investors own 79.15% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $13.00 price target on shares of MiMedx Group in a report on Thursday, February 27th. StockNews.com raised shares of MiMedx Group from a "buy" rating to a "strong-buy" rating in a research note on Friday, April 4th.

MiMedx Group Stock Up 0.4 %

Shares of MDXG traded up $0.03 on Tuesday, reaching $6.80. The stock had a trading volume of 485,159 shares, compared to its average volume of 695,406. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14. The firm has a market capitalization of $1.00 billion, a price-to-earnings ratio of 12.36 and a beta of 1.74. The company has a 50-day simple moving average of $7.82 and a 200-day simple moving average of $8.01.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, meeting the consensus estimate of $0.07. The business had revenue of $92.91 million during the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. Sell-side analysts predict that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Insider Buying and Selling

In other news, insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the sale, the insider now directly owns 310,836 shares of the company's stock, valued at approximately $2,452,496.04. This represents a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO William Frank Iv Hulse sold 81,446 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $7.80, for a total value of $635,278.80. Following the transaction, the chief accounting officer now owns 494,774 shares of the company's stock, valued at $3,859,237.20. The trade was a 14.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 144,018 shares of company stock valued at $1,130,312 over the last quarter. Corporate insiders own 1.30% of the company's stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.